NEWS CENTER
Poseida News Center
Featured Content
Read media coverage on Poseida, find resources for the working press, and get insights from our executive leadership team on how Poseida is advancing a new class of cell and gene therapies.
Poseida in the News
Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics
|
November 20, 2024
Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
|
November 17, 2024
CAR-T and Related Therapies Home In on Autoimmune Disease
|
November 4, 2024
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma
|
October 2, 2024
Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
|
October 2, 2024
“Off-the-Shelf” CAR T Therapy Strikes Hard Against Relapsed Myeloma
|
September 30, 2024
P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma
|
September 30, 2024
Poseida shares incremental Phase 1 update for Roche-partnered off-the-shelf CAR-T
|
September 30, 2024
Executive Perspectives
Press Releases
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
|
December 9, 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
|
November 26, 2024
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
|
November 14, 2024
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
|
November 14, 2024
Media Library
Usage rights & restrictions:
These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.
